0001193125-13-201475.txt : 20130506 0001193125-13-201475.hdr.sgml : 20130506 20130506154538 ACCESSION NUMBER: 0001193125-13-201475 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130506 DATE AS OF CHANGE: 20130506 EFFECTIVENESS DATE: 20130506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 13816025 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 d532220d13fhr.txt 13F HOLDINGS REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: March 31, 2013 Check here if Amendment [_]; Amendment Number: This Amendment (Check only one.): [_] is a restatement. [_] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Pascal Schmucki Title: SIGNING AUTHORITY Phone: 41 (44) 267 67 00 Signature, Place, and Date of Signing: /s/ Pascal Schmucki --------------------------------------- Schaffhausen, Switzerland, May 3, 2013 Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 3 Form 13F Information Table Entry Total: 19 ----------- Form 13F Information Table Value Total: $1,266,108 ----------- (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Form 13F File Number Name --- -------------------- -------------------- 1 28-11193 Biotech Focus N.V. 2 28-11191 Biotech Invest N.V. 3 28-11189 Biotech Target N.V. 2 BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 -------- -------- --------- -------- ------------------ ---------- -------- --------------------- VOTING AUTHORITY TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER --------------------- NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ---- Achillion Pharmaceuticals Inc COM 00448Q201 14,694 1,679,340 SH DEFINED 3 1,679,340 NONE NONE Alexion Pharmaceuticals Inc COM 015351109 66,101 717,400 SH DEFINED 2 717,400 NONE NONE Ariad Pharmaceuticals Inc COM 04033A100 52,198 2,887,075 SH DEFINED 3 2,887,075 NONE NONE Biomarin Pharmaceutical Inc COM 09061G101 25,982 417,310 SH DEFINED 2 417,310 NONE NONE Celgene Corp COM 151020104 263,137 2,270,186 SH DEFINED 2 2,270,186 NONE NONE Dendreon Corp COM 24823Q107 5,989 1,264,800 SH DEFINED 2 1,264,800 NONE NONE Endocyte Inc COM 29269A102 29,125 2,339,345 SH DEFINED 3 2,339,345 NONE NONE Gilead Sciences Inc COM 375558103 191,845 3,920,000 SH DEFINED 1 3,920,000 NONE NONE Halozyme Therapeutics Inc COM 40637H109 32,552 5,646,519 SH DEFINED 3 5,646,519 NONE NONE Idenix Pharmaceuticals Inc COM 45166R204 4,425 1,250,000 SH DEFINED 3 1,250,000 NONE NONE Immunogen Inc COM 45253H101 55,087 3,427,934 SH DEFINED 3 3,427,934 NONE NONE Incyte Corp COM 45337C102 124,398 5,313,870 SH DEFINED 3 5,313,870 NONE NONE Isis Pharmaceuticals Inc COM 464330109 130,339 7,694,172 SH DEFINED 3 7,694,172 NONE NONE Medivation, Inc COM 58501N101 58,436 1,249,706 SH DEFINED 3 1,249,706 NONE NONE Onyx Pharmaceuticals Inc COM 683399109 48,562 546,500 SH DEFINED 2 546,500 NONE NONE Optimer Pharmaceuticals Inc COM 68401H104 17,216 1,446,700 SH DEFINED 3 1,446,700 NONE NONE The Medicines Co COM 584688105 32,998 987,654 SH DEFINED 2 987,654 NONE NONE Theravance Inc COM 88338T104 20,980 888,244 SH DEFINED 3 888,244 NONE NONE Vertex Pharmaceuticals Inc COM 92532F100 92,044 1,674,445 SH DEFINED 3 1,674,445 NONE NONE
3